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1 Drug description 
Generic/Brand name: Gefitinib/Iressa® 
Developer/Company: Astra Zeneca 
Description: Gefitinib belongs to the group of tyrosine kinase inhibitors 
(TKIs). One mechanism of action is the inhibition of tyrosine kinases (TK) 
involved in the downstream signalling of the epidermal growth factor 
receptor (EGFR) [1]. These enzymes are expressed on the cell surface and 
are responsible for the growth and proliferation of normal as well as of 
tumour cells.  Activating mutations of the EGFR TK domain within cancer 
cells can be partially held accountable for tumour growth, blockage of 
apoptosis and an increased likelihood of metastasis [2].     
Several clinical characteristics have been identified which predict response 
to gefitinib treatment. These are female gender, non-smokers, patients of 
Asian ethnicity and individuals with bronchoalveolar adenocarcinomas [3-
7].  Within this group activating EGFR mutations are also more likely to be 
found [4, 7], hence, these characteristics might be used to select a population 
with an increased frequency of mutation rates which range in unselected 
Caucasian populations from 12% - 17% [8, 9] where gefitinib treatment 
might be more effective.  
The recommended way of administration is one 250 mg tablet Iressa® daily, 
taken orally. No clear recommendations on treatment duration were found, 
hence, it was assumed that treatment should continue as long as disease does 
not progress or as long as toxicity remains acceptable. 
2 Indication 
Gefitinib is indicated as first-line therapy for the treatment of locally ad-
vanced or metastatic non-small cell lung cancer (NSCLC) with activating 
mutations of EGFR TK.  
3 Current regulatory status 
The EMEA granted market authorization for gefinitib for the treatment of 
adult patients with locally advanced or metastatic NSCLC with activating 
mutations of EGFR TK in June 2009 [2].  
In the US, the FDA had approved gefitinib in 2003 but limited the indica-
tion in 2005 to monotherapy for the continued treatment of patients with lo-
cally advanced or metastatic NSCLC after failure of both platinum-based 
and docetaxel chemotherapies who are benefiting or have benefited from ge-
fitinib [10].   
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4 Burden of disease 
NSCLC is one of the leading types of cancer and causes of cancer deaths 
worldwide [11]. Its primary risk factors are first- and second-hand smoke 
exposition [12]. Men are still more often affected by NSCLC than women, 
with the majority of patients being diagnosed at an age ≥ 65 years [13]. On 
average, patients are aged 71 years at the time of diagnosis of NSCLC.  
About 3,400 people died of lung cancer and, overall, nearly 4,000 new cases 
of lung cancer were diagnosed in Austria in 2007 [14]. As NSCLC accounts 
for about 85% of all lung cancer cases [12, 15] of which 85% [16] can be ex-
pected to present with advanced disease, results in an estimated 2,900 per-
sons with advanced NSCLC per year. Applying estimates of an average fre-
quency of activating EGFR mutations (within an unselected population 
about 15%) to these numbers would give about 435 individuals with activat-
ing EGFR mutations and so, patients potentially eligible for treatment with 
Iressa®. 
Depending on certain tumour characteristics, for example tumour size, loca-
tion and invasion of the surrounding tissue, presence of metastasis in the 
lymph nodes or distant metastasis, the tumour node metastasis (TNM) sys-
tem is used for the staging of the disease. Locally advanced and metastasised 
NSCLC corresponds to TNM stage IIIB and IV, respectively. In addition to 
this staging, the histological subtype of the tumour and the patients’ per-
formance status, as well co-morbidities are taken into account in order to 
develop a treatment regimen. Wherever possible, therapy should be indi-
vidualized based on results of molecular (e.g. EGFR status) and other tu-
mour characteristics [6]. 
Prognostic factors are early-stage disease at diagnosis, good performance 
status according to the Eastern Cooperative Oncology Group (ECOG PS 0 - 
2), female gender and no significant weight loss [12]. Other prognostic and 
predictive factors for lung cancer response are, again, biomarkers like EGFR 
expression and mutational state, the occurrence of downstream signal trans-
duction pathway modifications (K-Ras mutation) and others [12].  
In 2005, the 1-year survival rate for patients with cancer of the lung and 
bronchus of all stages was 44.4% in the US [13]. The 5-year survival rate in 
NSCLC depends on both tumour stage and patient’s age at diagnosis and is 
17.2% for all stages of NSCLC. The 5-year survival rate for localized 
NSCLC is 54.2%, for regional 25.2%, for distant 3.7% and for unstaged 
8.5%. In individuals aged under 45 years it is 25.7% and decreases to 15.1% 
in patients > 65 years of age [13]. Median overall survival for patients with 
stage IIIB disease is about 10 months, for patients with stage IV it is 6 
months [17] and disease progression after first-line chemotherapy can be 
expected within 3 to 6 months after the initiation of therapy [15]. 
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5 Current treatment 
Treatment options for patients with advanced disease (TNM IIIB, IV) are  
 platinum based chemotherapy: modern regimens are mostly based 
on a platinum compound (cisplatin, carboplatin) in addition to one 
or two out of numerous other substances (e.g. vinorelbine, pacli-
taxel, docetaxel, gemcitabine, irinotecan) but for none of these 
combinations superiority has been established unequivocally.  
 other chemotherapy regimens: due to the toxicity of platinum based 
regimens, other drug combinations can be used (gemcitabine + do-
cetaxel/paclitaxel/vinorelbine/pemtrexed, paclitaxel + vinorelbine) 
 single agent chemotherapy as first-line treatment is generally used 
for elderly patients or for those with worse PS 
 radiation therapy 
 targeted therapies: EGFR inhibitors (erlotinib), monoclonale anti-
bodies (bevacizumab, cetuximab) 
 a combined modality approach [6]. 
6 Evidence 
Three phase III trials [8, 18, 19] and several other studies, including phase II 
trials, were identified. All phase III trials showed similar results in overall 
survival (OS) for patients treated with either gefitinib or chemotherapy. In 
patients with activating EGFR mutations, favourable results for progression-
free survival (PFS) were found in two of these studies [8, 18].  Quality of life 
(QoL) was an outcome measure in two trials and demonstrated better results 
for the gefitinib group. Adverse events occurred less frequent in the Iressa® 
groups than in the chemotherapy groups.  
The phase II studies varied in terms of study population and interventions. 
Accordingly, differences in outcomes were observed with OS ranging from 
3.7 months to 17.5 months and PFS between 3.2 months to 9.2 months. Se-
vere side effects were generally rare but interstitial lung disease, a major 
complication believed to be associated with gefitinib, was observed in up to 
7.5% of the study population.  
Two retrospective analyses which included only patients with EGFR muta-
tions were found. Both demonstrated prolonged PFS for the gefitinib group, 
but results on OS differed. 
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6.1 Efficacy and safety - phase III studies 
Reference  IPASS trial, published [8] NEJ002, unpublished, abstract available [18] first-SIGNAL study, unpublished, conference presentation 
available [19, 20] 
Sponsor Astra Zeneca  Astra Zeneca 
Country China, Hong Kong, Indonesia, Japan, Malaysia, Philippines, Singapore, Tai-
wan, Thailand 
Japan Korea 
Design phase III, open-label, multicenter, randomized controlled trial multicenter phase III randomized phase III 
Participants  
characteristics 
I 609 pts: median age 57 yrs, range 24-84 yrs; 79.5% women, 93.8% never 
smoker 
C 608 pts: median age 57 yrs, range 25-84 yrs; 79.1% women, 93.6% 
never smoker 
 
EGFR status determined in 437 pts out of which 59.7% had EGFR muta-
tions overall; I=132 pts, C=129 pts 
I 98 pts: median age 63 years, 63% women, 97% 
stage IV, 90% adenocarcinoma   
C 100 pts: median age 63 years, 64% female, 75% 
stage IV, 96% adenocarcinoma 
I 159 pts vs C 150 pts, 
89% women 
EGFR status determined in 96 pts (31.1%) out of which 42 
pts were EGFR mutation positive 
Treatments I(ntervention): gefitinib 250 mg daily, administered orally 
C(ontrol): first-line chemotherapy with paclitaxel (day 1: 200 mg/m2 body 
surface area) + carboplatin (dose calculated to produce area under con-
centration time curve of 5.0-6.0/ml/min iv. once every 3 weeks up to 6 cy-
cles) 
 
treatment continued until disease progression, unacceptable side effects 
occurred, or completion of 6 chemotherapy cycles, I group was allowed to 
cross-over to C group if tumour progressed 
                                 
I(ntervention): gefitinib 250 mg daily 
C(ontrol): carboplatin AUC1 6 + paclitaxel 200mg/m2 
in 21 day cycles 
I(ntervention): gefitinib 250 mg daily, administered orally q 
3 weeks 
 C(ontrol):  1250mg/m2 gemcitabine (d 1 and d8) + 
80mg/m2 cisplatin (d 1) q 3 weeks x 9 cycles       
 
post-study use of EGFR TKIs in 81% of patients in chemo-
therapy group                       
In-/exclusion criteria previously untreated patients in East Asia, NSCLC stage IIIB or IV, non 
smokers (<100 cigarettes in their lifetime) or light smokers (≤10 pack-
years, or quit smoking ≥ 15 yrs before), ECOG PS 0 to 2,  
previously untreated  with sensitive EGFR muta-
tions, ECOG PS 0-1 
previously untreated, never-smokers, adenocarcinoma, 
ECOG PS 0-2, stage IIIB or IV, 
Follow-up median: 5.6 months interim analysis   
Outcomes Primary: progression-free survival (PFS) 
Secondary: overall survival (OS), objective response rate (ORR), quality of 
life (QoL), adverse events 
Primary: progression-free survival (PFS) 
Secondary: overall survival (OS), response rate, qual-
ity of life (QoL), adverse events 
overall survival (OS), progression-free survival (PFS), objec-
tive response rate (ORR), quality of life (QoL), adverse 
events 
Key results  
 
Primary:  
- median PFS: I 5.7 months vs C 5.8 months 
- 12-month rates of PFS: I 24.9% vs C 6.7% 
Primary: PFS I 10.4 months vs C 5.5 months, HR = 
0.357, p<0.001  
 
Median OS:  
I 21.3 months vs C 23.3 months; HR=1.003 (95%CI 0.749 to 
1.343, p= 0.428) 
                                                             
1 AUC = area under curve 
2 FACT-L = functional assessment of cancer therapy, lung 
3 TOI= trial outcome index 
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- HR (for progression or death) = 0.74 (95% CI 0.65 to 0.85, p<0.001)  
- EGFR positive subgroup analysis: HR (progression) = 0.48 (95% CI 0.36 
to 0.64, p<0.001) 
- EGFR negative subgroup analysis: HR (progression) = 2.85 (95% CI 2.05 
to 3.98, p<0.001) 
 
Secondary: 
OS: median survival: I 18.6 months vs C 17.3 months 
HR (for death in I group)= 0.91 (95%CI 0.76 to 1.10) 
EGFR positive subgroup analysis: HR = 0.78 (95% CI 0.50 to 1.20) 
EGFR negative subgroup analysis: HR= 1.38 (95% CI 0.92 to 2.09) 
 
- ORR: I 43% vs C 32.2%, OR=1.59 (95% CI 1.25 to 2.01, p<0.001) 
- EGFR positive subgroup analysis: ORR: I 71.2% vs C 47.3% (p<0.001) 
- EGFR negative subgroup analysis: I 1.1% vs C 23.5% (p=0.001) 
 
 
QoL: FACT-L2 questionnaire OR=1.34 (95% CI 1.06 to 1.69, p=0.01) 
EGFR positive subgroup FACT-L QoL improvement rate: 70.2% vs 44.5%, 
p<0.0001 
EGFR negative subgroup FACT-L QoL improvement rate: 14.6% vs 36.3%, 
p=0.0021 
TOI3: OR= 1.78, (95%CI 1.4 to 2.26, p<0.001) 
 
Secondary:  
OS I 28.0 months vs C 23.6 months, p=0.353  
response rate: I 74.5% vs 29.0%, p<0.001 
EGFR positive: I 30.6 months vs C 26.5 months, HR= 0.82 
(95%CI 0.35 to 1.92, p= 0.65)  
EGFR negative: I 18.4 months vs 23.3 months, HR=1.2 
(95%CI 0.57 to 2.52, p= 0.63) 
 
Median PFS: I 6.1 months vs C 6.6 months; HR= 0.813 
(95%CI 0.641 to 1.031, p=0.044) 
EGFR positive: I 8.4 months vs C 6.7 months, HR= 0.61 
(95%CI 0.31 to 1.22, p= 0.08)  
EGFR negative: I 2.1 months vs 6.4 months, HR=1.5 (95%CI 
0.88 to 2.62, p= 0.07) 
 
Objective response: OR4 = 1.39 (95%CI 0.89 to 2.17, 
p=0.15), DCR5= 0.54 (95%CI 0.32 to 0.9, p=0.02) 
 
ORR6: EGFR positive: I 84.6% vs C 37.5%, OR= 9.17 (95%CI 
2.11 to 39.85, p= 0.002) 
EGFR negative: I 25.9% vs C 51.9% , OR= 0.33 (95%CI 0.10 
to 1.02, p=0.05) 
 
DCR: EGFR positive: I 88.5% vs C 100%, p= 0.28 
EGFR negative: I 40.7% vs C 81.5%, OR= 0.16 (95%CI 0.05 
to 0.54, p=0.002) 
 
QoL: more favourable outcomes for I group for global 
health status, role functioning, social functioning 
Adverse effects 
(AEs) 
overall grade 3/4 AEs: I 28.7 vs C 61.0% 
discontinuation due to AEs: I 6.9% vs C 13.6% 
Deaths associated with AEs: I 3.8% vs C 2.7% 
Serious AE, including death: I 16.3% vs C 15.6% 
AEs leading to hospitalization: I 13.8% vs C 13.1% 
ILD7 events all grades/grade 3,4 ,5 : I 2.6% vs C  1.4%/I 1.3% vs C 0.2% 
neutropenia grade 4: I 1% vs C 33%, grade 3-4 liver 
dysfunction I 25% vs C 1% 
grade 3 neuropathy 0% vs 5%, p<0.01 
more favourable outcomes for I group for appetite loss, pe-
ripheral neuropathy, alopecia 
grade 5 ILD: I 2 pts 
Commentary EGFR mutation was a robust predictor of improved PFS with gefitinib, in-
dicating that patients in whom an EGFR mutation has been identified will 
benefit most from first-line therapy with gefitinib. 
gefitinib as the first-line treatment for advanced 
NSCLC harbouring EGFR mutations significantly im-
proves PFS with favourable toxicity profiles against 
chemotherapy, thus should be considered as new 
standard treatment for sensitive EGFR mutation-
positive NSCLC pts 
EGFR mutation status strong predictive marker for overall 
response and PFS with gefitinib, unprecedented survival 
outcome along with high ORR and better toxicity profile, 
gefitinib might be reasonable first-line therapy for never-
smoker lung adenocarcinoma pts 
                                                                                                                                                                                                                                                                                                                 
4 OR= odds ratio 
5 DCR= disease control rate (complete remission + partial remission + stable disease)  
6 ORR= objective response rate (complete remission + partial remission) 
7 ILD = interstitial lung disease 
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Previously untreated patients suffering from NSCLC were randomized to ei-
ther gefitinib treatment or to a platinum based chemotherapy with the main 
objective of showing the non-inferiority of gefitinib in comparison to stan-
dard chemotherapy. The population included consisted mainly of women 
(overall 80%) of Asian origin, patients with good performance status and 
never smokers (94%), factors all known to impact positively on the treat-
ment with EGFR TKIs [8]. Nevertheless, EGFR mutation status was not a 
prerequisite for inclusion, leading to determination of EGFR status in 
35.9% of patients. Out of these 437 samples, 261 (60%) had a confirmed 
positive EGFR mutation status, resulting in 132 EGFR mutation positive 
patients treated with gefitinib and 129 individuals treated with chemother-
apy. 
For the gefitinib group, favourable results for PFS were found, especially if 
a planned subgroup analysis according to EGFR mutational status was per-
formed but, as mentioned above, these subgroups were considerably small. 
Similarly, QoL showed also superior results for the gefitinib group, fore-
most, if mutational status was taken into account. On the other hand, no 
benefit in terms of OS was demonstrated - but follow-up is still ongoing. De-
spite higher overall frequencies of adverse events of grade 3 or 4 in the che-
motherapy group, serious adverse events, such as deaths associated with 
treatment occurred slightly more often after the administration of gefitinib. 
Interstitial lung disease was seen nearly twice as often in the intervention 
group than in the chemotherapy group.  
A further phase III trial conducted in Japan (only abstract available) com-
pared patients with confirmed EGFR mutations treated with either gefitinib 
or carboplatin + paclitaxel [18]. Similar to the trial mentioned above, OS 
was not statistically different in between the groups, but PFS showed a dif-
ference of 4.9 months in favour of the gefitinib group. Regarding side effects, 
neutropenia and neuropathy occurred less frequent, liver dysfunctions more 
often in the Iressa® group.  
On the 13th conference on lung cancer,  Lee et al. [19] presented results of the 
“first‐SIGNAL” study – a randomized phase III trial assessing first‐line ther‐
apy with gefitinib in comparison to gemcitabine + cisplatin. The study popu‐
lation  comprised  309  never‐smokers  suffering  from  adenocarcinoma  and 
with an ECOG PS 0‐2. EGFR status was determined  in 96 patients of whom 
42  had  activating  EGFR  mutations.  OS  did  not  differ  even  if  a  subgroup 
analysis according to EGFR status was performed. Median PFS showed over‐
all better outcomes for the gefitinib group, results which were not repeated 
when only patients with activating EGFR mutations were taken into account. 
According  to  the  presentation,  gefitinib  was  superior  to  standard  chemo‐
therapy  in  terms of QoL  related measures and  in a number of  selected ad‐
verse events.  
6.2 Efficacy and safety - further studies 
Several phase II trials were identified which evaluated first-line gefitinib for 
the treatment of advanced or metastasised NSCLC.  
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One randomized phase II study compared chemo-naïve patients with poor 
PS which were treated with best supportive care either in combination with 
gefitinib (100 patients) or with placebo (101 patients) [21]. Neither PFS nor 
OS (median OS 3.7 months for gefitinib group vs 2.8 months for placebo 
group) nor QoL showed statistically significant improvements for the inter-
vention group. An analysis in patients with EGFR FISH- positive (fluores-
cent in situ hybridization) tumours, however, demonstrated more favourable 
outcomes in terms of PFS for the gefitinib group (HR=0.29, 95% CI 0.11 to 
0.73) but this group consisted of only 32 patients.  
Two studies concentrated on patients with EGFR mutations [9, 22]. Sample 
size was 16 in a trial conducted in Japan [9], and 31, mainly non Asians, in 
another study [22]. Both trials included more women and a high proportion 
of never smokers (38% and 46%). Median PFS was 8.9 to 9.2 months and ob-
jective response rates were observed in 58% to 81% with the majority being 
partial responses. Sequist et al. calculated a projected median OS of 17.5 
months. An objective response was achieved in 12 patients (2 complete re-
sponses, 10 partial responses) [9] and 17 patients (1 complete response, 16 
partial responses) [22].  
Five further phase II trials assessing first-line gefitinib were found [23-27]. 
Sample size varied from 34 patients [27] to 70 patients [24]. Median OS dif-
fered substantially. The shortest OS was 6.3 months in a study which in-
cluded mainly individuals with history of smoking, poor ECOG PS and with 
a median age of 75 years [24]. The longest OS of 14.1 months was found in a 
study conducted in Japan [27]. Median age was 64 years and patients had 
good PS. In the other studies, OS ranged from 9.6 months, evaluated in an 
older population (median age 75 years) which had received chemotherapy 
with docetaxel additionally to gefitinib [23], to 11.5 months [25]. Results of 
median PFS fluctuated from 3.2 months [26] to 6.9 months [23].  
QoL was assessed in three studies [21, 25, 27]. One trial found, depending on 
the instrument used for evaluation, improvements in 15% to 41% of pa-
tients, but  the majority of patients remained stable [25]. The study by Su-
zuki et al. [27] observed no changes in global health status, but significant 
improvements in insomnia, appetite loss and gastrointestinal side-effects, 
whereas the last study did not find improved outcomes for the intervention 
group [21].  
Regarding side-effects, the vast majority were mild or moderate and in-
cluded rash (up to  55%) or diarrhoea (51%)  [21, 26]. More severe adverse 
events of grade 3 occurred in up to 17%, consisting of fatigue [24, 27], hepa-
totoxicity [9, 27], haematological side effects [23, 25], or rash [27]. Grade 4 
events were relatively rare and comprised deep vein thrombosis or pulmo-
nary embolus in about 3% [24] and grade 4 anaemia in up to 6% [9, 23]. Re-
ports on interstitial lung disease, a serious complication related to gefitinib 
treatment [6], were found in four studies and occurred in up to 7.5% of all 
patients [9, 22, 23, 26].  Three studies did not observe any pulmonary toxici-
ties [21, 25, 27] in patients treated with gefitinib. Treatment discontinuation 
because of drug related toxicity was reported in only two studies [9, 22]. 
A pooled analysis of five reports, comprising 101 patients with EGFR muta-
tion, found a median PFS of 7.7 to 12.9 months. OS had just been reached in 
one of the trials included and was 15.4 months [3]. Two of the reports evalu-
ated first-line gefitinib and the remaining ones assessed a mixed population 
treated with gefitinib first-line therapy or after exposure to chemotherapy.  
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Morita et al. performed a combined survival analysis of seven phase II trials 
incorporating results from 148 patients with EGFR mutations which had re-
ceived gefitinib either as first-line therapy (87 patients) or after chemother-
apy (61 patients) [4]. At a median follow-up time of 20.7 months, median 
PFS was 9.7 months (95% CI 8.2 to 11.1 months) and median OS was 24.3 
months (95% CI 19.8 to 28.2 months). Good ECOG PS (0, 1) and no prior 
chemotherapy were significantly associated with improved results for PFS 
and OS. When the first-line gefitinib group was compared to those patients 
who had previously received systemic chemotherapy, PFS was significantly 
extended for the first-line group, whereas no differences were found for OS.  
A retrospective analysis compared 51 chemonaïve never smokers treated 
with gefitinib and gemcitabine-carboplatin to a historical cohort of 29 never 
smokers treated with gemitabine-carboplatin alone [28]. Adding gefitinib to 
the chemotherapy resulted in an improved PFS (adjusted HR=0.19, 95% CI 
0.0105 to 0.351, p<0.001) and median OS increased from 14.1 months in the 
chemotherapy only group to 20.5 months (p=0.05).  
7 Estimated costs 
Cost estimates for one package containing 30 tablets 250 mg Iressa® range 
between € 2,463 [29] and € 3,601 [30]. It remains unclear whether the major-
ity of costs will be in addition to or instead of other forms of therapy by rea-
sons that the EMEA approval does not clearly state whether gefitinib should 
be used as monotherapy or in combination with chemotherapy. Neverthe-
less, at the moment clinical practice is in clear favour of monotherapy.    
It was assumed that treatment should continue as long as disease does not 
progress or as long as toxicity remains acceptable. In the phase III trial men-
tioned above [8], median duration of treatment was 6.4 months, hence as-
suming treatment lasting on average for 6 months, would result in € 14,616.- 
to € 21,606.-. However, by sparing patients the considerable side-effects as-
sociated with platinum-based chemotherapies, gains in QoL-related out-
come measures as well as diminished expenses for in-patient treatment have 
to be taken into account.   
8 Ongoing research 
Two open phase III studies were identified on clinicaltrials.gov  
NCT01017874, which is not yet recruiting, will compare first-line gefinitib 
alone or in combination with chemotherapy (pemetrexed/cisplatin) for the 
treatment of NSCLC in never- smoking patients with East Asian origins. 
NCT00807066, a study conducted in Italy, has an estimated completion date 
in November 2011 and will compare patients with locally advanced or me-
tastatic NSCLC treated with either first-line platinum based chemotherapy 
or first-line gefintinib.  
other study designs... 
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Moreover, the final publications of the NEJ002 and first-SIGNAL are ex-
pected.  
Plenty phase II trials were found additionally, assessing gefitinib for differ-
ent indications such as maintenance therapy, in combination with hy-
droxochloroquine or with radiation therapy or for the treatment of carcino-
matous meningitis in patients with NSCLC.  
9 Commentary - English 
In June 2009, the EMEA granted market authorization for gefitinib for the 
treatment of advanced or metastatic NSCLC with activating mutations of 
EGFR TK. The decision for approval as first-line therapy was mainly based 
on the results of the IPASS study [8] which assessed first-line monotherapy 
with gefitinib in selected patients (mainly younger, women with Asian ori-
gin, non-smokers), where EGFR TKI treatment is the most effective. Within 
this highly selected population, OS did not differ between patients treated 
with gefitinib or standard chemotherapy - but follow-up is still ongoing. 
PFS, on the other hand, showed favourable results for the population treated 
with gefitinib (HR=0.74, 95% CI 0.65 to 0.85, p<0.001). Moreover, in a pre-
planned subset analyses, PFS and QoL scores were significantly improved in 
patients with activating EGFR mutations. Nevertheless, as a positive EGFR 
mutational status was determined in only 261 patients, this group was, over-
all, considerably small.  
Regarding adverse events, the gefitinib group experienced less often events 
of grade 3 or 4 than the chemotherapy group. Interstitial lung disorders were 
more common in the gefitinib group (2.6%) than in the chemotherapy group 
(1.4%) and slightly more deaths associated with adverse events occurred in 
the intervention group (I 3.8% vs C 2.7%). Overall however, treatment with 
gefitinib was better tolerated than chemotherapy, indicating that it should 
be used as monotherapy and not in combination with other chemotherapeu-
tic agents. 
Two further phase III trials were found [19, 20]. Both trials were also con-
ducted in an Asian setting, included more females than males and one study 
assessed gefitinib treatment only in never-smokers. These studies did not 
show any difference between gefitinib and chemotherapy in terms of OS. 
With regards to PFS, results differed. One of the trials evaluated Iressa® 
therapy in a study population with confirmed activating EGFR mutations 
and showed a difference of 4.9 months in favour of the EGFR-TKI group 
(p<0.001) [18]. The “first-SIGNAL” study on the other hand, did not con-
firm these results within a subgroup of 42 patients with activating EGFR 
mutations [19]. The adverse events mentioned, such as alopecia, neutropenia 
or neuropathy, occurred less often if gefitinib was administered, leaving 
liver dysfunction the only side-effect more common in this treatment arm. 
QoL related outcome measures were presented for the “first-SIGNAL” 
study, indicating benefits for gefitinib over chemotherapy.  
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Despite data indicating that patients with EGFR mutations might benefit 
eventually from gefitinib, studies assessing its value in a population repre-
sentative for the majority of NSCLC patients in Europe are missing. Accord-
ingly, EMEA’s Committee for Medicinal Products for Human Use expressed 
concerns whether results stemming from an Asian population can be used to 
extrapolate efficacy of gefitinib to a Caucasian population. EMEA’s Scien-
tific Advisory Group concluded that because gefitinib shows “across all stud-
ies [...] a consistent pattern of activity in EGFR mutation status positive pa-
tients” [31] a confirmatory first-line study is not necessary, but a post-
marketing prospective trial within a Caucasian population with confirmed 
EGFR mutations should be conducted. As a consequence, Astra Zeneca has 
agreed on developing, in accordance with the EMEA, an appropriate trial 
design [31]. 
Another issue which has been discussed repeatedly is the method for detect-
ing EGFR mutations [8, 9, 28]. In addition to the absence of standardized 
methods, challenges include the acquisition of enough tumour tissue for 
analysis which might be particularly difficult in patients with advanced dis-
ease whom are not candidates for surgery [28]. Moreover, mutational status 
might differ depending on where the tissue has been derived from (i.e. pri-
mary tumour vs metastatic lesions) [6] and mutations, possibly leading to an 
acquired drug resistance against EGFR TKIs, may even occur during ther-
apy. With the possibility of an acquired drug resistance, regular monitoring 
of the cancer’s genotype might become necessary [6, 32]. These resulting un-
certainties impact not only on the potential clinical benefit but also on the 
financial burden as determination of EGFR status prior to and even during 
EGFR TKI treatment, would increase costs further. It is also debatable 
whether current study findings justify repeated biopsies in critically ill pa-
tients. On the other hand, gains in QoL can be expected by sparing patients 
considerable toxicities associated with platinum-based chemotherapies.  
Undoubtedly, the oral application of gefitinib in an outpatient setting and, 
in general, less severe side-effects in comparison to chemotherapy offer ad-
vantages. Nevertheless, a number of issues surrounding first-line gefitinib 
therapy for NSCLC still remain unresolved, making it difficult to conclu-
sively judge its potential clinical benefit. However, this drug might prove 
quite effective if used in patients identified by more refined molecular tar-
geting.   
10 Commentary – German 
Die EMEA erteilte im Juni 2009 für Gefitinib die Marktzulassung für die 
Behandlung von erwachsenen PatientInnen mit lokal fortgeschrittenem oder 
metastasiertem, nicht-kleinzelligem Lungenkarzinom (NSCLC) mit aktivie-
renden Mutationen der EGFR TK.  
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Die Entscheidung für die Zulassung als Erstlinientherapie basierte im We-
sentlichen auf den Ergebnissen der IPASS Studie [8], welche die Erstli-
nienmonotherapie mit Iressa® in einer ausgewählten Studienpopulation 
(jüngere PatientInnen, Frauen von asiatischer Herkunft, Nichtraucher), in 
der Therapien mit EGFR TKIs sehr wirksam sind, untersucht hatte. In die-
ser hoch selektierten PatientInnengruppe, zeigte sich in Bezug auf Gesamt-
überleben kein Unterschied zwischen Iressa® und Standardchemotherapie - 
das Follow-up ist allerdings noch nicht abgeschlossen. Das progressionsfreie 
Überleben (PFS) hingegen, zeigte bessere Ergebnisse für die Gefitinib-
Gruppe als für die Chemotherapiegruppe (HR=0,74; 95% CI 0,65 bis 0,85, 
p<0,001). In einer geplanten Subgruppenanalyse in Patienten mit EGFR 
Mutationen wurde ebenfalls eine statistisch signifikante Verbesserung von 
sowohl PFS, als auch der Lebensqualität gefunden. Nichtsdestotrotz soll er-
wähnt werden, dass EGFR aktivierende Mutationen in insgesamt nur 261 
PatientInnen nachgewiesen wurden und diese Subgruppe daher relativ klein 
war.  
In Bezug auf unerwünschte Nebenwirkungen von Grad 3 und Grad 4 wur-
den diese seltener in der Gefitinib-Gruppe als in der Chemotherapiegruppe 
beobachtet. Interstitielle Lungenerkrankungen (I 2,6% vs C 1,4%) als auch 
Therapieassoziierte Todesfälle (I 3,8% vs C 2,7%) traten jedoch häufiger un-
ter Therapie mit Iressa® auf. Insgesamt war Gefitinib aber besser verträglich 
als Chemotherapie, sodass die Iressa®  Monotherapie mit eher angezeigt 
scheint, als eine Kombinationstherapie.  
Zwei weitere Phase III Studien [18, 19], die ebenfalls in Asien durchgeführt 
worden waren, wobei in beiden Studien mehr Frauen als Männer und in ei-
ner nur Nichtraucher eingeschlossen worden waren [19], zeigten für Gefiti-
nib und Chemotherapie keine Unterschiede hinsichtlich Gesamtüberleben. 
In Bezug auf PFS waren die Ergebnisse unterschiedlich: Eine Studie, welche 
Iressa®  in einer  Studienpopulation mit aktivierenden EGFR Mutationen 
bewertet hatte, fand eine Differenz von 4,9 Monaten zu Gunsten der mit 
EGFR-TKI behandelten Gruppe (p<0.001) [18]. Die „first-SIGNAL” Studie 
hingegen zeigte für diese PatientInnensubgruppe, welche allerdings nur aus 
42 PatientInnen bestand, keinen Vorteil [19]. Unerwünschte Nebenwirkun-
gen, wie etwa Alopezie, Neutropenie oder Neuropathie, waren seltener in 
der Gefitinibgruppe zu beobachten, lediglich Dysfunktionen der Leber tra-
ten häufiger auf. Auch für die Lebensqualität zeigten sich günstigere Ergeb-
nisse für die mit Iressa® behandelte Gruppe [19].  
Nichtsdestotrotz sind Studien ausständig, die den Wirksamkeitsnachweis 
für eine im europäischen Kontext relevante Population mit NSCLC erbrin-
gen. EMEAs Ausschuss für Humanarzneimittel äußerte Bedenken, ob die 
Ergebnisse einer asiatischen Studienpopulation auf eine kaukasische Bevöl-
kerung umlegbar seien. Der wissenschaftliche Beirat der EMEA  folgerte 
aber, dass für Gefitinib „aufgrund des durch alle Studien hinweg durchwegs 
einheitlichen Aktivitätsprofils in PatientInnen mit positiven EGFR Status“ 
[31] keine bestätigende Erstlinienstudie mehr nötig sei. Allerdings sollte im 
Weiteren eine Anwendungsbeobachtungsstudie in einer klar definierten, 
kaukasischen PatientInnengruppe mit nachgewiesener EGFR Mutation 
durchgeführt werden [31]. Astra Zeneca, der Hersteller, erklärte sich einver-
standen, unter Rücksprache mit der EMEA eine entsprechende Studie 
durchzuführen.  
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Zusätzlich soll erwähnt werden, dass bisher kein einheitlicher Standard zur 
Bestimmung des EGFR Status existiert [8, 9, 28] und vor allem bei Patien-
tInnen, die aufgrund eines fortgeschrittenen Stadiums der Erkrankung kei-
ne Kandidaten für ein operatives Vorgehen sind, es schwierig sein kann, 
ausreichend Tumorgewebe zur Bestimmung des EGFR Status zu gewinnen 
[28]. Zusätzlich wird diskutiert, dass je nach dem woher Gewebe gewonnen 
wurde (Primärtumor, Metastasen), der Mutationsstatus unterschiedlich sein 
kann [6]. Da es auch während einer EGFR TK Therapie zu einer erworbe-
nen Resistenz gegen EGFR TKIs kommen kann, könnte ein regelmäßiges 
Monitoring des EGFR Status nötig sein [6, 32]. Die daraus resultierenden 
Unsicherheiten könnten nicht nur auf den potentiellen therapeutischen 
Nutzen von Gefitinib Auswirkungen haben, sondern auch auf die Kosten, da 
der EGFR Status vor Gefitinibtherapie und in weiterer Folge auch während 
der Therapie bestimmt werden müsste. Diskussionswürdig ist auch, ob die 
derzeitige Datenlage wiederholte Biopsien in schwerkranken PatientInnen 
rechtfertigen kann. Durch die Vermeidung  von den mit Platinhältiger 
Chemotherapie verbundenen, schweren Nebenwirkungen kann aber auf der 
anderen Seite mit einer Verbesserung der Lebensqualität gerechnet werden.   
Zweifellos bietet Gefitinib aufgrund der oralen, ambulanten Einnahme und 
der, im Vergleich zu Chemotherapie, selteneren schwerwiegenden Neben-
wirkungen Vorteile. Allerdings sind noch etliche Fragen offen, die eine end-
gültige Einschätzung des therapeutischen Nutzens von Gefitinib für die 
Erstlinientherapie bei NSCLC erschweren. Die Substanz bietet aber durch-
aus das Potential, eine effektive Therapieoption in molekular noch besser zu 
charakterisierenden Patientenkollektiven zu werden. 
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